siRNA
siRNA Product Search
Search results can be refined by term and pathway selection.
Introduction
- Validated and rigorously tested in-house to ensure protein expression inhibition.
- CST antibodies allow for the confirmation of targeted protein silencing.
- siRNA Kits include Fluorescein labeled non-targeted siRNA duplex designed to monitor tranfection efficiency and siRNA specificity.
- Transfection reagent, from Mirus Corp., optimized for efficient siRNA delivery in mammalian cells.
Product Data
SignalSilence® Akt siRNA #6211
Western blot analysis of extracts from CHO cells, untreated or insulin-treated, transfected with non-targeted (-) or Akt (+) siRNA. Akt Antibody #9272 confirms silencing of protein expression while a non-targeted antibody, p42 MAPK Antibody #9108 was used to control for loading and specificity of Akt siRNA (A). Phospho-GSK-3β (Ser9) Antibody #9336 confirms downstream pathway inhibition (B).
SignalSilence® PTEN siRNA (Human Specific) #6251
Western blot analysis of extracts from HeLa cells transfected with non-targeted (-) or targeted (+) siRNA. PTEN was detected using the PTEN Antibody #9552, and p42 was detected using the p42 MAPK Antibody #9108. The PTEN Antibody confirms silencing of PTEN expression, and the p42 MAPK Antibody is used to control for loading and specificity of PTEN siRNA.
New siRNA Products
| No. | Name | Released |
|---|---|---|
| 6446 | SignalSilence® XIAP siRNA (Human specific) | 07/26/2004 |
| 6445 | SignalSilence® XIAP siRNA Kit (Human Specific) | 07/26/2004 |
| 6426 | SignalSilence® MEK1 siRNA (Human Specific) | 07/08/2004 |
| 6425 | SignalSilence® MEK1 siRNA Kit (Human Specific) | 07/08/2004 |
| 6431 | SignalSilence® MEK2 siRNA (Human Specific) | 07/08/2004 |
| 6430 | SignalSilence® MEK2 siRNA Kit (Human Specific) | 07/08/2004 |
| 6385 | SignalSilence® Pool p38 MAPK siRNA Kit | 07/08/2004 |
| 6391 | SignalSilence® Pool p42 MAPK siRNA | 07/08/2004 |
| 6390 | SignalSilence® Pool p42 MAPK siRNA Kit | 07/08/2004 |
| 6436 | SignalSilence® p44 MAPK siRNA (Human Specific) | 07/08/2004 |
